四川科伦药业股份有限公司2026年度第一期科技创新债券发行结果的公告

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. has successfully issued its first phase of technology innovation bonds for 2026, raising funds for debt repayment and working capital [1][2]. Group 1 - The company received approval from the board of directors and shareholders for the issuance of non-financial corporate debt financing tools on April 22, 2025, and May 19, 2025, respectively [1]. - The company was granted a registration notice by the China Interbank Market Dealers Association on September 16, 2025, allowing for a medium-term note registration quota of RMB 3 billion, valid for two years [2]. - The first phase of the technology innovation bonds was issued on January 19, 2026, with the total funds raised credited to the company on January 20, 2026 [2]. Group 2 - The funds raised from this bond issuance will be used to repay existing debts and supplement working capital [2]. - As of the date of the announcement, the company is not classified as a dishonest entity [2].